What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($34.54); post-transaction worth based connected June 5, 2026 marketplace close.

Key questions

• How does this transaction align with Kunkel's humanities trading activity?
  This merchantability marks Kunkel's archetypal open-market disposition of Enliven Therapeutics communal stock, pursuing a past of administrative filings with nary anterior open-market income reported.

• What information of Kunkel's full nonstop holdings was affected?
  The transaction represented 16% of her nonstop communal banal holdings, reducing her involvement from 61,884 to 51,884 shares, with nary interaction connected immoderate indirect oregon derivative positions.

• Was the transaction executed nether a pre-arranged plan?
  Yes, the Form 4 notes that the income reported were effected pursuant to a Rule 10b5-1 trading program adopted connected March 6, 2026.

• What is the marketplace discourse for this sale?
  As of June 5, 2026, Enliven Therapeutics shares had returned 62.4% implicit the anterior year, and the transaction was completed astatine a weighted mean terms of $34.54, with the banal closing astatine $34.71 connected the transaction day and subsequently appreciating to $50 by Friday.

Company overview

Company snapshot

• Enliven Therapeutics develops tiny molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-mutant cancers; some candidates are successful Phase 1 objective trials.

• The steadfast operates a clinical-stage biopharmaceutical exemplary focused connected advancing proprietary oncology therapeutics done early-stage development, with aboriginal gross expected from merchandise commercialization oregon strategical partnerships.

• It targets oncologists, crab attraction centers, and biopharma partners addressing unmet needs successful hematologic and coagulated tumor oncology markets.

Enliven Therapeutics is simply a Boulder-based biotechnology institution specializing successful the find and objective improvement of caller small-molecule therapies for cancer. With a thin workforce and a absorption connected kinase inhibitors, the institution aims to code high-value oncology indications with important unmet need. Enliven's competitory borderline lies successful its targeted attack and advancement of differentiated assets successful early-stage objective trials.